G
Gyoungah Ryu
Researcher at Gyeongsang National University
Publications - 4
Citations - 51
Gyoungah Ryu is an academic researcher from Gyeongsang National University. The author has contributed to research in topics: Inflammation & Cancer. The author has an hindex of 1, co-authored 3 publications receiving 14 citations.
Papers
More filters
Journal ArticleDOI
Phytochemicals as Anti-Inflammatory Agents in Animal Models of Prevalent Inflammatory Diseases
Seong Ah Shin,Byeong Jun Joo,Jun Seob Lee,Gyoungah Ryu,Minjoo Han,Woe Yeon Kim,Hyun Ho Park,Jun Hyuck Lee,Chang-Sup Lee +8 more
TL;DR: The characteristics of phytochemicals that possess anti- inflammatory activities in various chronic inflammatory diseases are discussed and the molecular signaling pathways altered by these anti-inflammatory phytochemical mechanisms are reviewed, with a focus on transcription factor pathways.
Journal ArticleDOI
Physiological Roles of Apoptotic Cell Clearance: Beyond Immune Functions
Minjoo Han,Gyoungah Ryu,Seong-Ah Shin,Jangeun An,Huiji Kim,Daeho Park,Dae-Hee Lee,Chang-Sup Lee +7 more
TL;DR: A review of the current understanding of the mechanisms and fundamental roles of apoptotic cell clearance and the beneficial roles in physiological processes such as differentiation and development can be found in this paper.
Journal ArticleDOI
Wistin Exerts an Anti-Inflammatory Effect via Nuclear Factor-κB and p38 Signaling Pathways in Lipopolysaccharide-Stimulated RAW264.7 Cells
TL;DR: It is found that wistin significantly reduced the production of nitric oxide and intracellular reactive oxygen species in lipopolysaccharide-stimulated RAW 264.7 cells and is a prospective candidate for the development of anti-inflammatory drugs.
Journal ArticleDOI
Anti-cancer effects of lucidadiol against malignant melanoma cells
Seong-Ah Shin,Jun Seob Lee,Byeong Jun Joo,Gyoungah Ryu,Minjoo Han,Huiji Kim,Jangeun An,Man Hyung Koo,Ui Joung Youn,Jun Hyuck Lee,Hyun Ho Park,Chang-Sup Lee +11 more
TL;DR: In this paper, a triterpenoid isolated from Ganoderma lucidum, called lucidadiol, was shown to significantly reduce B16 melanoma cell viability in a dose-and time-dependent manner.